

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/576,121
		Filing Date	January 22, 2007
		First Named Inventor	Jerome B. Zeldis
		Art Unit	1617
		Examiner Name	Manu M. Manohar
		Attorney Docket Number	9516-314-999
Sheet	1	of	3

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ —Number ⁴ —Kind Code ⁵ (if known)				
	B1	WO 2004/041190	05-21-2004	CELGENE CORPORATION		
	B2	WO 2004/041181	05-21-2004	CELGENE CORPORATION		
	B3	WO 00/02564	01-20-2000	THE UNIVERSITY OF SYDNEY		
	B4	WO 03/014315	02-20-2003	THE CHILDREN'S MEDICAL CENTER CORP		
	B5	WO 02/058730	08-01-2002	ALLERGAN SALES, INC.		
	B6	WO 2004/027027	04-01-2004	TRUSTEES OF THE UNIV. OF PENNSYLVANIA		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND**

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/576,121
		Filing Date	January 22, 2007
		First Named Inventor	Jerome B. Zeldis
		Art Unit	1617
		Examiner Name	Manu M. Manohar
		Attorney Docket Number	9516-314-999
Sheet	2	of	3

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)		THE CHILDREN'S MEDICAL CENTER CORP		
	B7	WO 02/064083	08-22-2002			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/576,121
		Filing Date	January 22, 2007
		First Named Inventor	Jerome B. Zeldis
		Art Unit	1617
		Examiner Name	Manu M. Manohar
Sheet	3	of	3
		Attorney Docket Number	9516-314-999

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
	C1	Supplementary European Search Report		
	C2	SPAIDE et al., Combined Photodynamic Therapy with Verteporfin and Intravitreal Triamcinolone Acetonide for Choroidal Neovascularization, Ophthalmology, Vol. 110, No. 8, 1 Aug 2003, p. 1517-1525		
	C3	HUNT et al., Consequences of the photodynamic treatment of resting and activated peripheral T lymphocytes, Immunopharmacology Vol. 41, No. 1, 1 Jan 1999, p. 31-44		
	C4	KRUGER et al., Short-term Oral Pentoxyfylline Use Increases Choroidal Blood Flow in Patients With Age-related Macular Degeneration, Arch. Ophthalmol., Vol. 116, No. 1, 1 Jan 1998, p. 27-30		
	C5	CIULLA et al., Changing therapeutic paradigms for exudative age-related macular degeneration: antiangiogenic agents and photodynamic therapy, Exp. Opin. Invest. Drugs, Vol. 8, No. 12, 1 Dec 1999, p. 2173-2182		
	C6	FINE et al., Age-related Macular Degeneration, New England Journal of Medicine, Vol. 342, No. 7, 17 Feb 2000, p. 483-492		
	C7	AMBRUS et al., Study of Antiangiogenic Agents with Possible Therapeutic Applications in Neoplastic Disorders and Macular Degeneration, Journal of Medicine, Vol. 31, No. 5-6, 1 Jan 2000, p. 278-282		
	C8	RICHARDSON et al., Thalidomide in multiple myeloma, Biomed Pharmacother, Vol. 56, No. 3, May 2002, p. 115-128		
	C9	BRIEGEL et al., Immunomodulation in Septic Shock: Hydrocortisone Differentially Regulates Cytokine Responses, Journal of the American Soc. of Nephrology, Vol. 12, Suppl. 17, Feb 2001, p. S70-S74		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.